Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shionogi-ViiV

- PMLiVE

Pfizer wins new European approval for Prevenar 13

Expands use of pneumococcal disease vaccine to cover people aged 18 to 49

- PMLiVE

GSK signs $500m-plus technology deal with Immunocore

Will make use of ImmTAC technology to activate immune system to kill cancerous or infected cells

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

- PMLiVE

GSK’s Botox sales in China under scrutiny says WSJ

Newspaper says it has reviewed company documents that discuss giving kickbacks to doctors to prescribe Botox

- PMLiVE

GSK’s Philip Thomson named Communiquetor of the Year

Recognised for stewardship of pharma company's global communications team

- PMLiVE

GSK’s personalised cancer drug Tafinlar set for European approval

Regulatory advisors recommend the melanoma drug be licensed

- PMLiVE

GSK’s muscular dystrophy drug ‘a breakthrough’ says FDA

The antisense oligonucleotide is being developed by GlaxoSmithKline and Prosensa

UK launch for Pfizer’s long-acting contraceptive injection Sayana

Becomes first contraceptive of its kind to reach the UK market

Synexus South Africa research sites join Pfizer trial network

CRO's sites become the first in Africa to meet the pharma company's standards

National Institute for Health and Care Excellence NICE logo

NICE U-turn on GSK’s Revolade

Watchdog says yes to blood disorder drug three years after initial knockback

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

GSK fires senior Chinese scientist over data fabrication

Pharma company dismisses head of Chinese R&D unit after tip-off about inaccurate MS data in journal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links